2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1298

Advocating for Rheumatoid Arthritis and Cardiovascular Health (ARCH): A Collaborative and Systems-Based Approach to Improve Access to Care
Abstract Number: 1431

Age and Sex Impacts the Development of Hypersensitivity in the Murine Partial Medial Menisectomy Model of Osteoarthritis
Abstract Number: 2284

Age and Sex Stratified Normative Data for Shoulder Range of Movement
Abstract Number: 1325

Age Effects Joint Space Narrowing in Early Active Rheumatoid Arthritis Patients
Abstract Number: 1533

Age Related Disability in Daily Life Should be Considered in Older Than Sixty-Five-Year-Old Rheumatoid Arthritis Patient
Abstract Number: 1165

Age-Dependent Effects of HLA-B27/β2m Expression on Host Immunity and the Intestinal Microbiota
Abstract Number: 2580

Age-Related Differences in Collagen-Induced Arthritis: Clinical, Imaging and Biological Characteristics in Juvenile Compared to Adult Animals
Abstract Number: 57

Age, Gender, Racial and Comorbidity Differences Among Systemic Lupus Erythematosus Patients Hospitalized with Ischemic Stroke Compared to the General Population: A Nationwide Analysis
Abstract Number: 157

Agreement Between DAS28, ACR/EULAR, SDAI, CDAI and Ultrasound Remission in Patients with Rheumatoid Arthritis Receiving Biological Treatment in Routine Care
Abstract Number: 2331

Agreement Between Patient’s and Physician’s Reported Bath Ankylosing Spondylitis Disease Activity Index in Patients with Axial Spondyloarthritis
Abstract Number: 182

Agreement Between Ultrasound and Radiography for the Detection of Rhizarthrosis
Abstract Number: 1002

Aiming for Remission in Early RA: Impact on Pain during the First Year of Treatment
Abstract Number: 10L

Aiming for Remission in Rheumatoid Arthritis: Clinical and Radiographic Outcomes from a Randomized Controlled Strategy Trial Investigating the Added Value of Ultrasonography in a Treat-to-Target Regimen
Abstract Number: 1215

Air Pollution and the Rheumatic Diseases: A Systematic Review and Meta-Analysis
Abstract Number: 1154

Ajulemic Acid Is a Novel Cannabinoid That Suppresses the Secretion of TNF-α and IFN-α from the Peripheral Blood Mononuclear Cells of DM Patients In Vitro

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].